Proteomics allows for the interrogation of how genetic predisposition influences disease progression and ultimately individual response when treatments become available. The SomaScan® Assay from Standard BioTools is the only proteomic technology capable of high-plex (measuring over half of the human proteome- 11,000 protein measurements), high throughput (rapidly), with high sensitivity (high-and low-abundance proteins). This state-of-art technology is enabled by SOMAmer® (Slow Off-rate Modified Aptamer) reagents that provide a highly specific and reproducible protein quantification tool which has been used from biomarker discovery to clinical and diagnostic methods.
The five major features of the SomaScan Platform, high specificity (powered by extensive reagent characterization and validations), high sensitivity through wide dynamic range (from fM to μM), high reproducibility (inter-plate average of 5% CV), low sample volume for a variety of sample types, and robust data normalization (no data bridging needed for key sample types) are the main drivers that drive use of the SomaScan technology for large cohort studies.
The variety of Standard Biotools product offerings, from the SomaScan 11K Assay for Discovery, Pre-Analytical Variation (PAV) tests (to assess sample handling impact), to SomaSignal Tests (SSTs) which provide multiple clinical assessments (LDT versions), and through RUO versions of SSTs, create a unique tool for discovering previously unidentified biomarkers for drug discovery, pre-clinical and clinical drug development, and clinical research, across a wide range of important diseases and conditions.